Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mattar

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Neuroimage|October 6, 2025
Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficitsLayth S Mattar, Shraddha Shah, Lily S Chamakura, et al.
Medrxiv : the Preprint Server for Health Sciences|June 30, 2025
Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficitsLayth S Mattar, Shraddha Shah, Lily S Chamakura, et al.
Journal of Neurosurgery|May 1, 2026
Subgaleal versus white matter reference for stereo-electroencephalography recordings: comparison of clinical impact and signal qualityDavin Devara, Zahra Jourahmad, Danika L Paulo, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Nature Cancer|October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Cancer Research|July 2, 2026
A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic StrategiesFilemon S Dela Cruz, Daoqi You, Tamar Y Feinberg, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Neuroimage|October 6, 2025
Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficitsLayth S Mattar, Shraddha Shah, Lily S Chamakura, et al.
Medrxiv : the Preprint Server for Health Sciences|June 30, 2025
Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficitsLayth S Mattar, Shraddha Shah, Lily S Chamakura, et al.
Journal of Neurosurgery|May 1, 2026
Subgaleal versus white matter reference for stereo-electroencephalography recordings: comparison of clinical impact and signal qualityDavin Devara, Zahra Jourahmad, Danika L Paulo, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Nature Cancer|October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Cancer Research|July 2, 2026
A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic StrategiesFilemon S Dela Cruz, Daoqi You, Tamar Y Feinberg, et al.
Pageof 5